

|  |  |
| --- | --- |
| **Examination question paper:**  | **July 2025** |

|  |  |
| --- | --- |
| **Module code: CY6051****Component number: 002** |  |
| **Module title: Systems Pharmacology** |  |
| **Module leader: Dr Chris Bax** |  |

|  |  |
| --- | --- |
| **Date:** | **July 2025** |
| **Duration:** | **1 Hour 30 Minutes** |

|  |  |
| --- | --- |
| **Exam type:** | Part Seen/Part Unseen, Closed |
| **Materials supplied:** | **None** |
| **Materials permitted:** | **None** |
| **Warning:** | **Candidates are warned that possession of unauthorised materials in an examination is a serious assessment offence.** |

|  |  |
| --- | --- |
| **Instructions to candidates:** | **You are advised to spend 60% of your time on Section A, and 40% on Section B****Maximum marks possible: 100** |
|  |  |
|  |  |
|  | Do not turn page over until instructed |

© London Metropolitan University

**SECTION B**

Maximum marks for Section B: 40

Answer **one** question in the answer book provided.

13. Using named examples, discuss the modes of action of chemotherapeutic agents used to treat bacterial infections.

**40 marks**

14. Discuss the rationale which underlies the use of the different classes of drugs indicated in the pharmacological treatment of dysrhythmias.

**40 marks**

##

15. a) Describe the key features of the acute and chronic leukaemias.

15 marks

 b) Evaluate the pharmacological approach to treating acute lymphoblastic

 leukaemia.

**15 marks**

c) A patient is diagnosed with chronic myeloid leukaemia.

i. What is the drug of choice to treat this condition and what is its mode

 of action?

**5 marks**

ii. What problems might occur after long term usage of this drug?

**5 marks**

**End of Section B**